Extended Duration of Adjuvant Temozolomide in Glioblastoma Multiforme - A Review of Trials

被引:0
|
作者
Pruthi, Deep Shankar [1 ]
Nagpal, Puneet [1 ]
Pandey, Manish [1 ]
机构
[1] Act Canc Hosp, Dept Radiat Oncol, A-4, New Delhi, India
来源
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY | 2021年 / 5卷 / 03期
关键词
Adjuvant; Glioblastoma Multiforme; Extended duration; Temozolomide; NEWLY-DIAGNOSED GLIOBLASTOMA; RANDOMIZED PHASE-III; PROLONGED TEMOZOLOMIDE; OPEN-LABEL; RADIOTHERAPY; CONCOMITANT; SURVIVAL; THERAPY;
D O I
10.14744/ejmo.2021.20733
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) chemotherapy then adjuvant TMZ is the current standard treatment for glioblastoma multiforme (GBM). There is a lot of controversy regarding the duration of adjuvant TMZ. The standard guidelines recommend 6 months of adjuvant treatment, however in clinical practice in a lot of centers around the world, TMZ therapy is continued beyond 6 months duration. In this review article we will discuss both favorable and unfavorable trials regarding extended TMZ therapy and try to analyze in whom extended TMZ therapy is beneficial and whether or not it should be offered.
引用
收藏
页码:217 / 221
页数:5
相关论文
共 50 条
  • [31] Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme
    Briceno, Eduardo
    Calderon, Alejandra
    Sotelo, Julio
    SURGICAL NEUROLOGY, 2007, 67 (04): : 388 - 391
  • [32] Concurrent Temozolomide and Radiation, a Reasonable Option for Elderly Patients With Glioblastoma Multiforme?
    Kimple, Randall J.
    Grabowski, Sarah
    Papez, Michael
    Collichio, Frances
    Ewend, Matthew G.
    Morris, David E.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (03): : 265 - 270
  • [33] Adjuvant Temozolomide for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies
    Zhao, Yan
    Wu, Jie
    Shi, Lunbo
    CLINICAL NEUROPHARMACOLOGY, 2021, 44 (04) : 132 - 137
  • [34] Temozolomide and Other Potential Agents for the Treatment of Glioblastoma Multiforme
    Nagasawa, Daniel T.
    Chow, Frances
    Yew, Andrew
    Kim, Won
    Cremer, Nicole
    Yang, Isaac
    NEUROSURGERY CLINICS OF NORTH AMERICA, 2012, 23 (02) : 307 - +
  • [35] Primary spinal cord glioblastoma multiforme treated with temozolomide
    Hernandez-Duran, Silvia
    Bregy, Amade
    Shah, Ashish H.
    Hanft, Simon
    Komotar, Ricardo J.
    Manzano, Glen R.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2015, 22 (12) : 1877 - 1882
  • [36] Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme
    Fabian Baumann
    Miroslava Bjeljac
    Spyros S. Kollias
    Brigitta G. Baumert
    Sebastian Brandner
    Valentin Rousson
    Yasuhiro Yonekawa
    René L. Bernays
    Journal of Neuro-Oncology, 2004, 67 : 191 - 200
  • [37] Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme
    Baumann, F
    Bjeljac, M
    Kollias, SS
    Baumert, BG
    Brandner, S
    Rousson, V
    Yonekawa, Y
    Bernays, RL
    JOURNAL OF NEURO-ONCOLOGY, 2004, 67 (1-2) : 191 - 200
  • [38] Time trends in glioblastoma multiforme survival: the role of temozolomide
    Dubrow, Robert
    Darefsky, Amy S.
    Jacobs, Daniel I.
    Park, Lesley S.
    Rose, Michal G.
    Laurans, Maxwell S. H.
    King, Joseph T., Jr.
    NEURO-ONCOLOGY, 2013, 15 (12) : 1750 - 1761
  • [39] Effect of adjuvant extended temozolamide treatment in survival of patients with glioblastoma multiforme
    Yildirim, Berna Akkus
    Sumbul, Ahmet Taner
    Topkan, Erkan
    Ozdemir, Yurday
    Besen, Ali Ayberk
    Guler, Ozan Cem
    Sedef, Ali Murat
    Onal, Cem
    CUKUROVA MEDICAL JOURNAL, 2018, 43 (03): : 640 - 645
  • [40] Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?
    Besiroglu, Mehmet
    Demir, Tarik
    Shbair, Abdallah T. M.
    Yasin, Ayse Irem
    Topcu, Atakan
    Turk, Haci Mehmet
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2021, 31 (08): : 932 - 936